4.5 Article

Evaluation of the Atellica COAG 360 coagulation analyzer in a specialized coagulation laboratory

期刊

出版社

WILEY
DOI: 10.1002/jcla.24276

关键词

Atellica COAG 360; automated analyzer; coagulation; hemophilia; hemostasis

向作者/读者索取更多资源

This study evaluated the analytical performance of the Atellica COAG 360 analyzer in diagnosing bleeding disorders in a specialized coagulation laboratory. The results showed that the analyzer performed as expected and was equivalent to the BCS-XP in determining coagulation parameters, making it suitable for accurate diagnosis of bleeding disorders.
Background Diagnosis of bleeding disorders includes correct analysis of coagulation factors VIII, IX, XI, XII, XIII, II, V, VII, and X and von Willebrand antigen and activity. The aim of this study was to evaluate the analytical performance of the Atellica COAG 360 analyzer in a specialized coagulation laboratory with focus on specific coagulation parameters involved in the diagnosis of bleeding disorders. Methods Verification included assessment of precision, reference interval, and method comparison according to local guidelines. For FVIII (Chromogenix) and FIX (Rossix), extended verifications were performed with additional assessment of linearity, detection limit, and comparability to BCS-XP. Results The precision was below 5% (normal levels) and below 10% (abnormal levels) and either improved or similar when compared to expected target values from a BCS-XP. The locally established reference range agreed well (>= 80% of measured values within manufacturer's assigned ranges) for most of the methods. The lower limit of quantification was calculated to below 0.01 IU/ml for FVIII chromogenic (Chromogenix) and FIX chromogenic (Rossix), both with acceptable linearity. Bland-Altman analyses revealed generally good agreement between Atellica COAG 360 and BCS-XP in the determination of coagulation parameters, and differences between the two instruments did not result in any diagnostic change. Conclusions The results of the evaluation show that the Atellica COAG 360 analyzer performs as expected to target values and equivalent to BCS-XP for the diagnosis of bleeding disorders in a specialized coagulation laboratory providing service to a hemophilia treatment center (HTC).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据